Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2014—Affymetrix received FDA 510(k) clearance to market its CytoScan Dx assay, intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx is designed to help diagnose children’s developmental and intellectual disabilities more comprehensively by enabling a high-resolution, genome-wide analysis of genetic aberrations.
March 2014—Agilent Technologies introduced SureFISH ALK, ROS1, and RET break-apart translocation probes, expanding its offering of oligonucleotide-based fluorescent in situ hybridization products. The probes are repeat-free, able to target specific sequences of interest, and use high-fidelity oligos designed in silico.
March 2014—Waters Corp. announced three UNIFI Scientific Information System solutions: Waters Glycan Application Solution with UNIFI, Forensic Toxicology Screening Application Solution with UNIFI, and Natural Products Application Solution with UNIFI. Each application features a proprietary, comprehensive library of relevant molecules.
March 2014—Agilent Technologies introduced the IQFISH FFPE Hybridization buffer, which enables one-hour hybridization for FISH processing on formalin-fixed paraffin-embedded tissue samples.
March 2014—Medical Chemical’s Total-Fix stool fixative for ova and parasites is now patented. Total-Fix does not contain any mercury, formaldehyde, or PVA. It is a multi-use, single-vial system that preserves stool specimens for staining (Trichrome/iron hematoxylin), concentration, Giardia and Cryptosporidium antigens, and fluorescent assays. Total-Fix also preserves molecular material in stool for molecular (real PCR) assays.
Definiens received the 2013 Global Frost & Sullivan Award for Company of the Year for Global Tissue Diagnostics and Pathology Imaging Solutions.
March 2014—Helix Elite is the first molecular product line from Microbiologics. It includes 13 molecular standards—intended to facilitate the development, validation, and monitoring of molecular assays—for microorganisms that are difficult to grow or cannot be cultured, such as Cryptosporidium and norovirus.
March 2014—Enzo Life Sciences’ high-sensitivity Grp78/BiP ELISA kit is an endoplasmic reticulum-specific homologue of Hsp70, serving as a critical stress-sensing chaperone and regulator of the unfolded protein response (UPR). Grp78 helps fold misfolded proteins, prevent protein aggregation, and regulate protein degradation, synthesis, transportation, and oligomerization.
March 2014—Clarient Diagnostic Services, a GE Healthcare company, has modified its facility in Houston to support a full range of clinical diagnostic testing for cancer. The facility, which operates under the name SeqWright Genomic Services, is a CLIA-certified lab offering nucleic acid sequencing and genomics services.
March 2014—Qiagen last year enrolled molecular diagnostics laboratories in an early access program to complete the development of a Web-based solution to deliver faster, easier-to-use, and high-confidence clinical interpretation and reporting of observed gene variants in data from NGS-based tests.
